His abstract highlighted the positive impact of implementing an AI-enabled infusion scheduling workflow on clinical care in a high-volume cancer center.
His abstract highlighted the positive impact of implementing an AI-enabled infusion scheduling workflow on clinical care in a high-volume cancer center.
@ryannipp.bsky.social
@ryannipp.bsky.social
Thank you to our incredible attendees, speakers, and patient advocates for coming together to share actionable insights, elevate care delivery, and improve outcomes for the cancer community. 🧡
Thank you to our incredible attendees, speakers, and patient advocates for coming together to share actionable insights, elevate care delivery, and improve outcomes for the cancer community. 🧡
#ASCOQLTY26
@bidmc-cancercenter.bsky.social
@ascocancer.bsky.social
#ASCOQLTY26
@bidmc-cancercenter.bsky.social
@ascocancer.bsky.social
Is it helpful, & is there risk of over-regulating our way into another fax machine era in medicine? @andrewmibrahim.bsky.social @fumikochino.bsky.social
Is it helpful, & is there risk of over-regulating our way into another fax machine era in medicine? @andrewmibrahim.bsky.social @fumikochino.bsky.social
☕ Grab your coffee, build a plate, and join the discussion: https://bit.ly/3TmqXCW
☕ Grab your coffee, build a plate, and join the discussion: https://bit.ly/3TmqXCW
Ambient Artificial Intelligent Scribes in Oncology: Impact on Clinician Experience and Documentation Burden
Read the article: https://bit.ly/4hKEtJX
Ambient Artificial Intelligent Scribes in Oncology: Impact on Clinician Experience and Documentation Burden
Read the article: https://bit.ly/4hKEtJX
Huge range of use: some super-users, some not using at all. Overall, not reducing 'pajama time' but maybe helping some outliers.
Form your own opinion:
ascopubs.org/doi/pdf/10.1...
Huge range of use: some super-users, some not using at all. Overall, not reducing 'pajama time' but maybe helping some outliers.
Form your own opinion:
ascopubs.org/doi/pdf/10.1...
Industry payments to oncologists are associated with aggressive end-of-life care for patients with cancer.
-Slight ⬆️ aggressive EOL care among those who received payments
-However, is this a function of 3' centers seeing more patients at later lines of tx?
-Need to clarify research support vs personal $
#ASCOQLTY26
@thewonkologist.bsky.social @dusetzinas.bsky.social
Industry payments to oncologists are associated with aggressive end-of-life care for patients with cancer.
M13: Fezolinetant for hot flashes from breast cancer treatment. Funded by @bcrfcure.bsky.social, important because #breastcancer patients weren't included in original studies.
Significant ↓ in hot flash frequency compared to placebo!
M13: Fezolinetant for hot flashes from breast cancer treatment. Funded by @bcrfcure.bsky.social, important because #breastcancer patients weren't included in original studies.
Significant ↓ in hot flash frequency compared to placebo!
Curious to hear thoughts from others in oncology.
#ASCOQLTY26
Is it helpful, & is there risk of over-regulating our way into another fax machine era in medicine? @andrewmibrahim.bsky.social @fumikochino.bsky.social
Curious to hear thoughts from others in oncology.
#ASCOQLTY26